Sign In
Buy AGIO
$30.02
-2.73 (-8.34%)
At Close: Jul 31, 2026
Agios scraps blood cancer drug program after study miss
07:21am, Friday, 29'th May 2026
Agios Pharmaceuticals said on Friday it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show enough benefit.
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
07:00am, Friday, 29'th May 2026
Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE) --
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
12:11pm, Monday, 25'th May 2026
Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the only authorized therapy for a broad patient population.
AMSTERDAM--(BUSINESS WIRE)-- #Avanzanite--Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its par
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
09:15am, Friday, 22'nd May 2026
PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S., S
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
01:04pm, Tuesday, 19'th May 2026
Agios Pharmaceuticals NASDAQ: AGIO executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently subm
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
12:25pm, Wednesday, 13'th May 2026
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
09:31am, Tuesday, 12'th May 2026
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 202
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
07:55am, Saturday, 02'nd May 2026
The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
03:35pm, Thursday, 30'th Apr 2026
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
06:27pm, Wednesday, 29'th Apr 2026
There's power in the company's No. 1 molecule.
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
03:01pm, Wednesday, 29'th Apr 2026
Agios Pharmaceuticals, Inc. (AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
08:46am, Wednesday, 29'th Apr 2026
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.81. This compares to a loss of $1.55 per share a year ago.
Agios Reports First Quarter 2026 Financial Results and Provides Business Update
06:30am, Wednesday, 29'th Apr 2026
Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025 Strong initial U.S. commerci
